Imatinib . mesylate

Tyrosine kinase inhibitor



ALX-270-492-M025	25 mg	34.00 USD

ALX-270-492-M100	100 mg	93.00 USD

ALX-270-492-M500	500 mg	342.00 USD

Tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor kit and platelet-derived growth factor (PDGF) receptors.

Product Specification

Alternative Name:	STI-571, CGP-57148B

Formula:	C₂₉H₃₁N₇O . CH₃SO₃H

MW:	493.6 . 96.1

Purity:	≥98% (HPLC)

Appearance:	White to pale yellow crystalline powder.

CAS:	220127-57-1

MI:	14: 4902

Solubility:	Soluble in water; sparingly soluble in methanol. We do not recommend storing aqueous solutions for more than one day.

Long Term Storage:	+4°C

Please mouse over

Product Literature References

Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling: M.T. Weigel, et al.; Cancer Lett. 273, 70 (2009), Abstract;

Imatinib as a novel therapeutic approach for fibrotic disorders: J.H. Distler & O. Distler; Rheumatology (Oxford) 48, 2 (2009), Abstract;

Imatinib mesylate for the treatment of chronic myeloid leukemia: S. Soverini, et al.; Expert Rev. Anticancer Ther. 8, 853 (2008), (Review), Abstract;

Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?: F. Miselli, et al.; Transl. Oncol. 1, 177 (2008), Abstract;

Imatinib: C.E. de Kogel & J.H. Schellens; Oncologist 12, 1390 (2007), (Review), Abstract;

The kinase inhibitor imatinib--an immunosuppressive drug?: D. Wolf, et al.; Cancer Drug Targets 7, 251 (2007), (Review), Abstract;

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors: E. Buchdunger, et al.; J. Pharmacol. Exp. Ther. 295, 139 (2000), Abstract;

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative: E. Buchdunger, et al.; Cancer Res. 56, 100 (1996), Abstract;